TLR7/8 Agonist Loaded Nanoparticles Augment NK Cell-mediated Antibody-based Cancer Immunotherapy.
Sign Up to like & getrecommendations! Published in 2020 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.0c00271
Abstract: Activated natural killer (NK) cells can kill malignant tumor cells via granule exocytosis and secretion of IFN-ɣ, a key regulator of TH1 response. Thus, mobilization of NK cells can augment cancer immunotherapy, particularly that mediated… read more here.
Keywords: agonist loaded; antibody; cancer immunotherapy; tlr7 agonist ... See more keywords
Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors
Sign Up to like & getrecommendations! Published in 2022 at "ACS Nano"
DOI: 10.1021/acsnano.1c10709
Abstract: The generation of specific humoral and cellular immune responses plays a pivotal role in the development of effective vaccines against tumors. Especially the presence of antigen-specific, cytotoxic T cells influences the outcome of therapeutic cancer… read more here.
Keywords: immune responses; systemically administered; antigen specific; antigen ... See more keywords
Nanocarrier Co-formulation for Delivery of a TLR7 Agonist plus an Immunogenic Cell Death Stimulus Triggers Effective Pancreatic Cancer Chemo-immunotherapy.
Sign Up to like & getrecommendations! Published in 2022 at "ACS nano"
DOI: 10.1021/acsnano.2c06300
Abstract: Although toll-like receptor (TLR) agonists hold great promise as immune modulators for reprogramming the suppressive immune landscape in pancreatic ductal adenocarcinoma (PDAC), their use is limited by poor pharmacokinetics (PK) and off-target systemic inflammatory effects.… read more here.
Keywords: cell death; cell; delivery tlr7; immunogenic cell ... See more keywords
Antibody and TLR7 Agonist Delay Viral Rebound in SHIV-Infected Monkeys
Sign Up to like & getrecommendations! Published in 2018 at "Nature"
DOI: 10.1038/s41586-018-0600-6
Abstract: The latent viral reservoir is the critical barrier for the development of a cure for HIV-1 infection. Previous studies have shown direct antiviral activity of potent HIV-1 Env-specific broadly neutralizing antibodies (bNAbs) administered when antiretroviral therapy… read more here.
Keywords: viral reservoir; rebound; antibody; viral rebound ... See more keywords
P1-282The TLR7 Agonist Imiquimod Triggers Immunogenic Cell Death in Cancer Cells
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx621.031
Abstract: Methotrexate and azathioprine had been administered to the patients with RA and MCTD, respectively. All 6 patients were histologically diagnosed as diffuse large B cell lymphoma. Because of the use of immunosuppressive drugs, 2 patients… read more here.
Keywords: complete remission; 282the tlr7; one patient; tlr7 agonist ... See more keywords
MP01-20 TLR7/8-AGONIST-LOADED M1-MACROPHAGE-DERIVED NANOVESICLES PROMOTE THE POLARIZATION OF MACROPHAGES TO ENHANCE BLADDER CANCER IMMUNOTHERAPY
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Urology"
DOI: 10.1097/ju.0000000000000815.020
Abstract: INTRODUCTION AND OBJECTIVE:Tumor-associated macrophages (TAM) are abundant in many cancers including bladder cancer, and often display an immune-suppressive M2-like phenotype to fosters tumor growt... read more here.
Keywords: bladder cancer; agonist loaded; mp01 tlr7; bladder ... See more keywords
Abstract 4697: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment and holds potential for combination with immune checkpoint inhibitors
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-4697
Abstract: Recent successes in immuno-oncology have focussed primarily on the T-cell synapse, targeting co-activatory /inhibitory pathways to modulate T cell function. However, strategies that target tumor-resident myeloid cells may be required to fully exploit the therapeutic… read more here.
Keywords: immune checkpoint; medi9197; tlr7 agonist; tumor ... See more keywords
Abstract 2342: RO7119929, a TLR7 agonist prodrug, induces local inflammation of the tumor microenvironment (TME) by reprogramming myeloid cells in patients (pts) with advanced primary or metastatic liver cancers
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2342
Abstract: Background: It is hypothesized that TLR7 agonists reprogram myeloid cells in the TME, which may lead to activation of antitumor CD8 T effector cells and subsequently tumor cell death. The orally available TLR7 agonist prodrug… read more here.
Keywords: liver; ro7119929; tme; myeloid cells ... See more keywords
Abstract 4151: Anti-CEACAM5 immune stimulant TLR7/8 agonist antibody drug conjugate is a potent myeloid cell activator for the treatment of CEACAM5-expressing tumors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-4151
Abstract: Toll Like Receptor 7 and 8 (TLR7/8) agonists are a promising approach to treat tumors by harnessing the innate immune system to trigger anti-tumor innate and adaptive immunity. One of the main obstacles to the… read more here.
Keywords: cell; anti ceacam5; immune stimulant; ceacam5 ... See more keywords
Abstract CT096: Phase 1 study of RO7119929 (TLR7 agonist prodrug) in patients (pts) with advanced primary or metastatic liver cancers
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct096
Abstract: Background Agonists for TLR7, a major regulator of the innate immune response, have been tested in oncology across several nonclinical and clinical investigations due to their ability to stimulate T-cell mediated cancer cell killing. The… read more here.
Keywords: liver cancers; agonist prodrug; crs; study ... See more keywords
Abstract CT180: Activation of innate and adaptive immune response with a clinical stage TLR7 agonist prodrug PRTX007
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct180
Abstract: Background. PRTX007 is an orally administered prodrug of PRX034, a toll-like receptor 7 (TLR7) agonist that elicits an unprecedented pattern of systemic immune induction in non-human primates and in humans. Notably, there is no evidence… read more here.
Keywords: activation innate; prtx007; innate adaptive; adaptive immune ... See more keywords